about
SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic miceFrom stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modificationsAnimal models of leukemia: any closer to the real thing?An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.Adult acute erythroleukemia: an analysis of 91 patients treated at a single institutionRNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaCorrelation analysis of two-dimensional gel electrophoretic protein patterns and biological variables.Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.Array CGH in human leukemia: from somatics to genetics.β-catenin induces expression of prohibitin gene in acute leukemic cellsBone marrow mesenchymal stem cell-derived Wnt5a inhibits leukemia cell progression in vitro via activation of the non-canonical Wnt signaling pathway.Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia.Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.Genomic imbalances are confined to non-proliferating cells in paediatric patients with acute myeloid leukaemia and a normal or incomplete karyotype.p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaPrognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.Using functional genomics to overcome therapeutic resistance in hematological malignancies.The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML.Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression.C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in miceAdvances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaProspective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell markerBiology, risk stratification, and therapy of pediatric acute leukemias: an update.Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation.Wnt/β-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3β Dependent Manner.MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cellsTargeting cell cycle regulators in hematologic malignancies.MLL fusions: pathways to leukemiaTargeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.Genome-wide profiling reveals transcriptional repression of MYC as a core component of NR4A tumor suppression in acute myeloid leukemia.When epigenetics kills: MLL fusion proteins in leukemia.Cytokines in the differentiation therapy of leukemia: from laboratory investigations to clinical applications.A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cellsIDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
P2860
Q24685799-00D4D366-F49C-4238-9079-5FDE673EF6C1Q26860339-2A2E1982-EB7B-4CB2-BECB-97B494C7DED6Q27026520-01B3B78C-175B-4EE8-A0A1-18F6786BEB76Q27027207-C19D3989-F885-44A1-9064-2A7E851D590FQ27851909-31EDAF15-7C7A-4FD2-8106-A2BC56A93DFDQ28258018-95A4A5C4-5FED-486A-88E7-9C9D27EA0D33Q29617201-29EE439B-D2EF-4465-8110-2273F57DD074Q30477879-C085CD43-8F31-4173-B06C-BDC82A32B4D0Q31083322-A28BBCD9-A118-4EFE-A669-5CD1861B8CF9Q33397024-9ACCA524-DB7A-458C-B42C-9169CB8A844AQ33721147-F034667B-24D0-4BB3-94F3-F1F17B8F5F2BQ33778512-60F66F1E-285B-4567-8BFF-A512AE92845FQ33795018-0FF5B73E-BF50-4E51-B6E7-1EDCF0E5CDD4Q33886181-AE0B8E6F-7011-4394-9CD8-7C832E4D50C0Q33915185-AA351713-3140-4E8E-AAD3-550EF0FDB1C6Q33939071-7E31844A-740D-46DB-8AE6-1E9EFA8F1A6FQ33953631-352C0184-D98D-4B7D-88CC-B00600B36982Q34004131-15FB33FD-8FDA-4589-BF8C-60F0ABE46353Q34285937-0DC827F0-9698-4D8D-A04C-0B38B103FD28Q34401328-41FC8894-FFCB-4240-93E3-4CF96C8EFDF0Q34524753-E40F935A-EDF6-41C4-9D27-BA5777F9AEA0Q34563234-1CEFEB93-E6C1-4C81-BBBB-78C98F1687DEQ34572894-2F793638-E492-4DD4-BC95-A6954D7B6DC5Q34598109-542E2C9B-BEDE-4355-9660-9C85B8F24927Q34720554-3C5B6EE7-27BB-43F4-A3C1-8B1B95366E8FQ34764504-D1B5CD90-C82A-4CBC-8920-F01007A579D4Q34905557-7447E98F-D107-4E94-80D4-47D1D766D367Q34972224-FD8164B7-1855-41C0-88B3-94335308B97FQ35001632-FF4CE301-758E-428D-9D4A-4153ADC853CFQ35334436-AFEAA63C-D1E7-490C-ADFD-F488B47B5144Q35788362-71F63766-42E2-4079-99FF-4CA629577E52Q35979385-016F0F6F-8D2A-4608-BB28-548A0A871F6CQ36143147-1D002DED-EA44-4DC7-9001-22F227EE82CEQ36239212-0496C87A-41C9-4036-8F6F-5D9B347284F0Q36359510-B1556488-3D4B-4876-BEEF-D6F21DBEE7EBQ36447915-2CF5EE6A-E404-4AFA-A7F9-4AE3F177B145Q36502377-4DD091B6-BBE2-43DB-8878-41CB4A03B2E3Q36561772-45D688A2-871C-405F-925C-F45620310112Q36642902-377DAB8A-60F0-45B3-90EA-C2C202F26D12Q36654598-D232B1C8-7F85-4090-A4B8-348EFAE4DBF3
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The molecular basis of leukemia.
@ast
The molecular basis of leukemia.
@en
type
label
The molecular basis of leukemia.
@ast
The molecular basis of leukemia.
@en
prefLabel
The molecular basis of leukemia.
@ast
The molecular basis of leukemia.
@en
P2093
P1476
The molecular basis of leukemia.
@en
P2093
Carolyn A Felix
Craig T Jordan
D Gary Gilliland
P356
10.1182/ASHEDUCATION-2004.1.80
P577
2004-01-01T00:00:00Z